Zacks Research Has Negative Outlook for BDX FY2027 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Zacks Research dropped their FY2027 earnings per share estimates for Becton, Dickinson and Company in a research report issued to clients and investors on Monday, December 16th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $16.68 per share for the year, down from their previous estimate of $16.75. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm earned $3.42 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis.

Other equities research analysts have also issued research reports about the company. Evercore ISI lifted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average price target of $283.50.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $223.83 on Wednesday. The company has a market capitalization of $64.71 billion, a P/E ratio of 37.68, a P/E/G ratio of 1.64 and a beta of 0.41. The business has a fifty day simple moving average of $230.06 and a two-hundred day simple moving average of $233.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89.

Institutional Trading of Becton, Dickinson and Company

A number of large investors have recently modified their holdings of the business. Arete Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth about $767,000. Charles Schwab Investment Management Inc. boosted its stake in Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares in the last quarter. Nomura Asset Management Co. Ltd. grew its position in Becton, Dickinson and Company by 2.3% during the third quarter. Nomura Asset Management Co. Ltd. now owns 561,040 shares of the medical instruments supplier’s stock valued at $135,267,000 after acquiring an additional 12,845 shares during the last quarter. Benson Investment Management Company Inc. lifted its holdings in shares of Becton, Dickinson and Company by 13.2% in the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock worth $5,380,000 after acquiring an additional 2,602 shares during the last quarter. Finally, Swedbank AB boosted its stake in shares of Becton, Dickinson and Company by 1.8% in the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock valued at $36,367,000 after purchasing an additional 2,729 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Roland Goette sold 638 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares in the company, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.